Omeprazole A2845: Practical Guide for H+,K+-ATPase Research

Omeprazole is a research-grade H+,K+-ATPase inhibitor used in gastric acid secretion research, antiulcer activity studies, and experimental peptic ulcer disease models. The product is chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, with a molecular formula of C17H19N3O3S and a molecular weight of 345.42. Because a directly matched paper dataset is not supplied for this product workflow, the guidance below separates product-dossier values from practical laboratory recommendations that should be validated in the investigator’s assay system.

What This Product Solves

Many gastric acid secretion experiments require a reproducible inhibitor challenge rather than an undefined biological extract or an incompletely characterized compound. Omeprazole A2845 addresses that need by providing a characterized small molecule with approximately 98% purity and reported inhibitory activity against H+,K+-ATPase and histamine-induced acid formation.

The reagent is particularly useful when the study objective is to compare vehicle and inhibitor conditions, establish a concentration-response design, or confirm that an acid-secretory readout is sensitive to proton-pump inhibition. The dossier reports an IC50 of 5.8 μM for H+,K+-ATPase inhibition and an IC50 of 0.16 μM for histamine-induced acid formation. These values are reference points from the product information, not universal operating concentrations. Apparent activity can vary with enzyme preparation, biological model, incubation design, activation state, and assay readout.

For product identity, handling, and current specifications, consult the Omeprazole product page from APExBIO. Use the reagent within a controlled research workflow rather than treating the dossier values as evidence of clinical efficacy.

Protocol Parameters

Protocol Parameters

Use the following fields when building an assay worksheet. Product-dossier values are identified as such; recommendations for preparation and validation are workflow guidance.

• Assay: H+,K+-ATPase inhibition assay; Value: IC50 5.8 μM; Applicability: direct enzyme inhibition benchmarking; Rationale: provides a product-dossier reference point for designing a concentration series and comparing assay-dependent potency; Basis: product dossier.
• Assay: Histamine-induced acid formation assay; Value: IC50 0.16 μM; Applicability: cellular, tissue, or gastric acid secretion response models when histamine stimulation is part of the design; Rationale: supports selection of an appropriate response window, but should not be transferred directly to a different preparation without verification; Basis: product dossier.
• Assay: Stock-solution preparation; Value: solubility of at least 17.27 mg/mL in DMSO; Applicability: preparation of concentrated research stocks; Rationale: the compound is insoluble in water and ethanol, so DMSO is the dossier-supported solvent for initial dissolution; confirm clarity and precipitation after dilution into assay medium; Basis: product dossier for solubility and workflow recommendation for dilution checks.
• Assay: Identity and dose calculation; Value: molecular weight 345.42 and formula C17H19N3O3S; Applicability: molar conversion, electronic records, and lot verification; Rationale: use the stated molecular weight for preparing molar solutions and reconcile the label, certificate of analysis, and experiment record; Basis: product dossier.
• Assay: Material storage and solution management; Value: solid storage at -20°C; Applicability: long-term retention of unused material; Rationale: preserve the solid form at the specified temperature and avoid long-term storage of solution form; Basis: product dossier.

Workflow Setup and QC Checklist

Before the assay

• Record SKU A2845, lot information, stated purity, molecular weight, and formula before opening the container.
• Keep the solid at -20°C as specified. Allow the container to equilibrate in a controlled manner before opening so that condensation is minimized.
• Plan the stock concentration from the molecular weight and the intended assay range. Use DMSO for the initial stock because the dossier lists the compound as insoluble in water and ethanol.
• Prepare only the amount needed for the experiment or near-term use. The product information does not recommend long-term storage of solution form.

During preparation

• Use a clean, dry vessel and mix until the stock is visually uniform. Document the solvent, calculated concentration, preparation date, and operator.
• When diluting into aqueous assay medium, add the stock gradually with adequate mixing. Inspect the final preparation for turbidity, crystals, or surface material.
• Include a vehicle control that contains the same DMSO exposure as the Omeprazole condition. Keep the vehicle constant across the concentration series whenever possible.
• Use independent preparation records for enzyme assays and biological acid-secretion models. Do not assume that a concentration effective in one system will produce the same response in another.

Run acceptance checks

• Confirm that untreated, stimulated, and vehicle controls are behaving as expected before interpreting inhibitor activity.
• Repeat any condition showing visible precipitation, unexpected background, or a failed control response after correcting the preparation issue.
• Track plate position, incubation sequence, readout timing, and lot number. These details are important when comparing H+,K+-ATPase inhibition across runs.

For a broader product-oriented discussion of assay planning, Optimizing Gastric Acid Secretion Research with Omeprazole complements this guide by focusing on experimental use in gastric acid secretion and antiulcer studies. For more focused assay implementation, Technical Guide: Omeprazole (A2845) for H+,K+-ATPase Assays provides a related workflow perspective.

Common Failure Modes and Fixes

Incomplete dissolution

Problem: The stock remains cloudy or contains visible particles. Likely cause: use of water or ethanol, insufficient mixing, or exceeding the practical solubility of the selected preparation. Fix: use DMSO for the initial stock, recalculate the amount from the molecular weight, mix thoroughly, and confirm clarity before dilution. Do not treat a visibly heterogeneous stock as a quantitative dose.

Precipitation after dilution

Problem: A clear DMSO stock becomes turbid in aqueous assay buffer. Likely cause: the compound’s aqueous insolubility and rapid local solvent exchange. Fix: add the stock gradually into well-mixed medium, maintain a constant vehicle design, and inspect each working solution. If precipitation persists, redesign the stock and dilution scheme rather than interpreting the condition as a biological effect.

Weak or inconsistent inhibition

Problem: Replicates do not show a consistent response. Likely cause: variable enzyme or tissue preparation, unstable assay controls, inaccurate dilution, or a mismatch between the reported reference assay and the current model. Fix: verify control performance, recalculate molar concentrations, review incubation order, and establish a small pilot concentration series before committing to a full experiment.

Unexpected vehicle effects

Problem: The vehicle changes baseline secretion or assay signal. Fix: match DMSO exposure across all conditions, include a vehicle-only control, and assess vehicle tolerance in the specific model before interpreting Omeprazole activity.

Storage-related variability

Problem: Results differ after repeated handling. Fix: minimize unnecessary freeze-thaw or repeated opening, retain the material as a solid at -20°C, and avoid keeping prepared solutions for long-term use. Record shipping and receipt condition; small-molecule shipments are specified for blue-ice transport.

Scope and Limitations

Omeprazole A2845 is intended strictly for scientific research. It is not a diagnostic reagent, approved treatment, or basis for medical decision-making. The reported IC50 values should be used as assay-context references rather than guaranteed potency thresholds for every enzyme, cell, tissue, or peptic ulcer disease model.

The dossier establishes high-level identity, purity, solubility, storage, and reported inhibitory values, but it does not by itself define a complete protocol for every experimental system. Investigators should validate dose range, vehicle tolerance, exposure design, assay linearity, and control performance in their own model. Avoid extending findings from gastric acid secretion research to unrelated biological pathways without direct experimental support.

Conclusion

Omeprazole SKU A2845 is best used as a controlled H+,K+-ATPase inhibitor for mechanistic gastric acid secretion research and related antiulcer activity studies. A reproducible workflow depends on using DMSO for initial dissolution, maintaining matched vehicle controls, preserving the solid at -20°C, avoiding long-term solution storage, and treating dossier IC50 values as starting references rather than universal assay settings. Careful identity checks and precipitation monitoring will improve interpretability when the compound is used in enzyme, cellular, or experimental gastric models.